Tecovirimat has received approval in Europe for treating mpox based on promising animal studies. However, recent clinical trials involving patients infected with a concerning variant of the monkeypox virus revealed that the drug does not significantly expedite recovery. This development raises questions about the drug's effectiveness in humans, indicating that while regulatory bodies were influenced by early animal data, real-world application may not yield the expected benefits for patients suffering from this viral infection.
Despite approval in Europe, the antiviral tecovirimat may not substantially shorten recovery time for patients infected with mpox, as indicated by clinical trials.
Animal studies led to tecovirimat's approval for mpox treatment, but its efficacy in humans, particularly against a new variant, remains questionable after trials.
Collection
[
|
...
]